Avanafil-13C5
Avanafil-13C5 (TA1790-13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis[1][2][3].
Product Specifications
Product Name Alternative
TA1790-13C5
UNSPSC
12352005
Target
Endogenous Metabolite; Isotope-Labeled Compounds; NO Synthase; Phosphodiesterase (PDE)
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Endocrinology; Cardiovascular Disease
Smiles
COC1=C(Cl)C=C(CNC2=C(C(N[13C][13C]3=N[13C]=[13C][13C]=N3)=O)C=NC(N4[C@H](CO)CCC4)=N2)C=C1
Molecular Formula
C18 13C5H21ClN7O3
Molecular Weight
483.87
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
